RONDECABTAGENE AUTOLEUCEL, A DUAL-TARGETING CD19/CD20 CAR T-CELL THERAPY, EXHIBITS A MANAGEABLE SAFETY PROFILE WITH LOW RATES OF GRADE = 3 CRS AND ICANS IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Introduction

This mock abstract represents content that will later be loaded from the S3 object named soho2026.76d0a71.Abstract.html.

Methods

The study summarizes conference submission metadata, authorship, affiliations, topic classification, presenter details, and linked poster media.

Conclusion

These placeholder sections preserve the detail-page structure while the production integration is connected to MySQL and S3.